文献速递小儿泌尿与泌尿修复前列腺增生与排尿功能障碍

A型肉毒毒素单次与多次注射治疗儿童神经源性膀胱的尿动力学结局

Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
PubMed 文献 · J Urol · 2019-09-13

该单中心回顾性研究纳入30例接受膀胱内注射abobotulinum toxin A的儿童神经源性膀胱患者,比较首次与末次注射前后的尿动力学参数变化。结果显示注射后膀胱测压容量和最大神经源性逼尿肌过度活动压显著改善,且多次注射疗效维持;低顺应性组顺应性改善显著优于膀胱过度活动组。

要点

  • 膀胱内注射A型肉毒毒素可显著改善儿童神经源性膀胱的膀胱测压容量和最大逼尿肌过度活动压
  • 多次注射的尿动力学疗效与首次注射相当,未观察到疗效衰减
  • 低顺应性膀胱患者的顺应性改善显著优于膀胱过度活动患者

核心结论

  • 膀胱内注射abobotulinum toxin A可改善儿童神经源性膀胱的膀胱测压容量和最大神经源性逼尿肌过度活动压,且多次注射后疗效维持。
  • 低顺应性膀胱患者的顺应性改善显著优于膀胱过度活动患者。

研究设计与样本

  • 单中心回顾性研究,纳入30例接受abobotulinum toxin A治疗的儿童神经源性膀胱患者。
  • 其中15例(50%)接受多次注射,16例(53%)为膀胱过度活动型。
  • 比较首次注射前与首次注射后、末次注射后的影像尿动力学参数。

主要发现

  • abobotulinum toxin A注射后膀胱测压容量显著改善(p<0.0001)。
  • 最大神经源性逼尿肌过度活动压显著改善(p=0.0001)。
  • 总体顺应性无显著变化(p=0.25)。
  • 首次与末次注射间尿动力学参数无显著差异。
  • 膀胱测压容量改善(p=0.05)和最大逼尿肌过度活动压改善(p=0.25)在低顺应性与膀胱过度活动组间相似;低顺应性组顺应性改善显著优于膀胱过度活动组(p=0.016)。

临床怎么用

  • 对于儿童神经源性膀胱,膀胱内注射abobotulinum toxin A可作为改善膀胱容量和逼尿肌过度活动的治疗选择。
  • 多次注射可维持尿动力学疗效,低顺应性膀胱患者可能从顺应性改善中获益更明显。

局限性

  • 单中心回顾性研究,样本量较小(30例),可能存在选择偏倚。
  • 未设立对照组,无法排除其他治疗或自然病程的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intradetrusor botulinum toxin is an established part of the treatment pathway for pediatric patients with neurogenic bladder. We determined the urodynamic effect of single and multiple administrations of abobotulinum toxin A in pediatric patients with neurogenic bladder, and determined the urodynamic efficacy of abobotulinum toxin A in low compliance vs overactive bladders. MATERIALS AND METHODS: We conducted a single center retrospective review of all pediatric patients with neurogenic bladder treated with abobotulinum toxin A. Videourodynamic data on cystometric capacity, maximum neurogenic detrusor overactivity pressure and compliance were gathered before and after the first abobotulinum toxin A administration and after the last administration. Patients were divided into low compliance and overactive bladder groups depending on initial videourodynamics findings. Paired t-test was used to compare videourodynamic outcomes before vs after abobotulinum toxin A injection. The Mann-Whitney U test was used to compare bladder groups. RESULTS: A total of 30 patients were included in the study. Of these patients 15 (50%) received multiple abobotulinum toxin A injections. There were 16 patients (53%) with overactive bladder. Abobotulinum toxin A administration significantly improved cystometric capacity (p <0.0001) and maximum neurogenic detrusor overactivity (p=0.0001). Overall, compliance did not change significantly (p=0.25). There was no significant difference in urodynamic parameters between first and last abobotulinum toxin A injections. Improvement in cystometric capacity (p=0.05) and maximum neurogenic detrusor overactivity (p=0.25) was similar between the low compliance and overactive bladder groups. Compliance significantly improved in the low compliance group vs the overactive bladder group (p=0.016). CONCLUSIONS: Intradetrusor abobotulinum toxin A improves cystometric capacity and maximum neurogenic detrusor overactivity in pediatric patients with neurogenic bladder. This effect is maintained over multiple injections. Compliance is significantly improved in patients with low compliance bladder vs overactive bladder.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Naqvi S, Clothier J, Wright A, et al. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A. J Urol. 2019. PMID: 31518199. doi:10.1097/JU.0000000000000540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。